Literature DB >> 19901936

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

E Becher1, C G Roehrborn, P Siami, R P Gagnier, T H Wilson, F Montorsi.   

Abstract

This article reports the results of a post hoc analysis of the multicenter, randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) study, which aimed to investigate the effects of dutasteride (0.5 mg), tamsulosin (0.4 mg), and their combination on storage and voiding symptoms in 4844 men aged > or =50 years with moderate-to-severe lower urinary tract symptoms (International Prostate Symptom Score > or =12), prostate volume (PV) > or =30 cm(3) and PSA 1.5-10 ng ml(-1). After 24 months, combination treatment achieved significantly greater mean reductions in both voiding and storage symptoms than either monotherapy, in each of the three baseline PV tertiles (30 to <42, 42 to <58, > or =58 cm(3)). Dutasteride was as effective as tamsulosin for control of storage symptoms, but provided significantly greater relief of voiding symptoms than tamsulosin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901936     DOI: 10.1038/pcan.2009.37

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  8 in total

Review 1.  Dutasteride/tamsulosin: in benign prostatic hyperplasia.

Authors:  Gillian M Keating
Journal:  Drugs Aging       Date:  2012-05-01       Impact factor: 3.923

2.  Effects of barbed suture during robot-assisted radical prostatectomy on postoperative tissue damage and longitudinal changes in lower urinary tract outcome.

Authors:  Nobuhiro Haga; Noriaki Kurita; Tomohiko Yanagida; Soichiro Ogawa; Michihiro Yabe; Hidenori Akaihata; Junya Hata; Yuichi Sato; Kei Ishibashi; Osamu Hasegawa; Yoshiyuki Kojima
Journal:  Surg Endosc       Date:  2017-06-22       Impact factor: 4.584

3.  5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

Authors:  Robert J Hamilton; Stephen J Freedland
Journal:  BMC Med       Date:  2011-09-15       Impact factor: 8.775

4.  Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.

Authors:  Kang Jun Cho; Se Hee Kang; Hyo Sin Kim; Jun Sung Koh; Joon Chul Kim
Journal:  Int Neurourol J       Date:  2011-09-30       Impact factor: 2.835

5.  Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.

Authors:  Yassine Kamal Lyauk; Trine Meldgaard Lund; Andrew C Hooker; Mats O Karlsson; Daniël M Jonker
Journal:  AAPS J       Date:  2020-07-29       Impact factor: 4.009

6.  The impact of preoperative lower urinary tract symptoms medication on the functional performance of holmium laser enucleation of the prostate.

Authors:  Alexander Tamalunas; Thilo Westhofen; Melanie Schott; Patrick Keller; Michael Atzler; Christian G Stief; Giuseppe Magistro
Journal:  Cent European J Urol       Date:  2021-08-13

7.  Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan.

Authors:  Makoto Nakiri; Naoyuki Ogasawara; Hirofumi Kurose; Kosuke Ueda; Katsuaki Chikui; Kiyoaki Nishihara; Kazuhisa Ejima; Keiichiro Uemura; Kenta Murotani; Koichiro Muraki; Chikayuki Hattori; Etsuyo Ogo; Yoshitaka Morimatsu; Tatsuya Ishitake; Tsukasa Igawa
Journal:  J Contemp Brachytherapy       Date:  2022-04-07

8.  Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.

Authors:  Bob Djavan; Seyed Saeid Dianat; Amir Kazzazi
Journal:  Patient Relat Outcome Meas       Date:  2011-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.